Dr. Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, University Professor of Neuroscience at Arizona State University (ASU), Professor of Psychiatry at the University of Arizona, Clinical Director of Neurogenomics at the Translational Genomics Research Institute (TGen), and Director of the Arizona Alzheimer’s Consortium. He is also interim Director of the ASU-Banner Neurodegenerative Research Center (NDRC).
He received his undergraduate and medical education at Duke University and his Psychiatry Residency Training at Duke and Washington University, and launched his career in brain imaging research under the mentorship of Marcus Raichle at Washington University in St. Louis. He has played leadership roles in brain imaging, brain mapping, and genomics research, the unusually early detection and tracking of Alzheimer’s disease (AD), and the accelerated evaluation of Alzheimer’s prevention therapies. More recently he has become actively involved in the development and use of blood-based Biomarkers and the discovery of APOE-related disease mechanisms and treatments. He has also sought to advance new models of biomedical research collaboration and dementia care.
Dr. Reiman and his Banner Alzheimer’s Institute colleagues established the Alzheimer’s Prevention Initiative (API) to launch a new era in Alzheimer’s prevention research. API includes public-private partnerships, prevention trials and biomarker development programs in cognitively unimpaired persons at high genetic and/or biomarker risk for AD, unusually large registries and innovative programs to support enrollment in these and other studies, precedent-setting trial data and biological sample sharing agreements, and other efforts to help find and support the approval, affordability and availability of prevention therapies as soon as possible.
Dr. Reiman is an author of about 500 publications, a principal investigator of six current NIH grants, and a member of the National Advisory Council on Aging (NIA Council). He is a recipient of the Potamkin Prize for his pioneering contributions to the study of preclinical AD and the accelerated evaluation of AD prevention therapies.